drugset / Trial / NCT01431430

VITamine D Supplementation in RenAL Transplant Recipients - VITALE

NCT01431430

RandomizedParallel-groupDouble-blindTreatment

Summary

It has been proposed that the intake of high dose of cholecalciferol may have beneficial non classical effects (beside bone health). This could include the reduction of type 2 diabetes mellitus, cardiovascular diseases, cancers, autoimmune and infectious diseases. These pleiotropic effects are mostly documented by observational and experimental studies or small intervention trials. In renal transplant recipients, vitamin D insufficiency, defined as circulating 25(OH)vitamin D (25OHD) less than 30 ng/mL, is a frequent finding and this population is at risk of the previously cited complications.The primary purpose of this study is to compare the effects of high dose vs. low dose of cholecalciferol on a composite endpoint consisting in de novo diabetes mellitus, cardiovascular diseases, de novo cancer and patient death.Renal transplant recipients between 12 and 48 months after transplantation will be randomized to blindly receive either high or low dose of cholecalciferol with a follow-up of 2 years.

Timeline

Start
2012-01-06
Primary completion
2016-02-02
Completion
2016-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 12000 iu
Subject Cholecalciferol Other / unclassified 100000 iu

Indications

No indication recorded.